Similar articles

• Current status of the use of 1,25(OH)2D3 in the management of renal osteodystrophy.

  Massry SG, Goldstein DA, Malluche HH. Massry SG, et al. Kidney Int. 1980 Oct;18(4):409-18. doi: 10.1038/ki.1980.154. Kidney Int. 1980. PMID: 7014981 Review. No abstract available.
• Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.

  Chesney RW, Hamstra A, Jax DK, Mazess RB, DeLuca HF. Chesney RW, et al. Contrib Nephrol. 1980;18:55-71. doi: 10.1159/000403273. Contrib Nephrol. 1980. PMID: 7353380 No abstract available.
• The effect of 1alpha(OH)D3 and 1alpha,25(OH)2D3 on the bone in patients with renal osteodystrophy.

  Bordier P, Zingraff J, Gueris J, Jungers P, Marie P, Pechet M, Rasmussen H. Bordier P, et al. Am J Med. 1978 Jan;64(1):101-7. doi: 10.1016/0002-9343(78)90184-5. Am J Med. 1978. PMID: 623125
• Evidence that different vitamin D sterols have qualitatively different effects in man.

  Rasmussen H, Bordier P. Rasmussen H, et al. Contrib Nephrol. 1980;18:184-91. doi: 10.1159/000403286. Contrib Nephrol. 1980. PMID: 7353375 No abstract available.
• Treatment of renal osteodystrophy with calciferol (vitamin D) and related steroids.

  Brickman AS, Norman AW. Brickman AS, et al. Kidney Int. 1973 Aug;4(2):161-7. doi: 10.1038/ki.1973.95. Kidney Int. 1973. PMID: 4364427 Review. No abstract available.